GlassScriptPhysician profile
Paul D O'Connell
NPI 1578527875
$4,031.30
in general payments reported to CMS, 2019-2025
26 companies · $1,275 in 2025
The $1,275 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.06 · 2022: $513 · 2023: $498 · 2024: $1,722 · 2025: $1,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,495.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $534.78 | 2022-2025 | Xyosted |
| Endo USA, INC. | $448.33 | 2024-2025 | Aveed, Xiaflex |
| E.R. Squibb & Sons, L.L.C. | $367.98 | 2024-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $333.92 | 2023-2025 | Wegovy, Ozempic |
| Amgen INC. | $310.80 | 2023-2025 | Repatha, Repatha |
| Endo Pharmaceuticals INC. | $265.50 | 2021-2024 | Aveed, Xiaflex |
| Tolmar, INC. | $254.59 | 2023-2024 | |
| Pfizer INC. | $239.23 | 2023-2025 | |
| Lilly USA, LLC | $179.87 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Acerus Pharmaceuticals Corporation | $156.23 | 2022 | |
| Novartis Pharmaceuticals Corporation | $143.91 | 2024-2025 | |
| Esperion Therapeutics, INC. | $139.56 | 2023-2025 | Nexletol |
| Teleflex LLC | $125.15 | 2022-2023 | Urolift |
| Janssen Biotech, INC. | $101.60 | 2024 | Akeega, Erleada |
| Heartflow, INC. | $81.29 | 2023-2025 | Ffrct |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $58.71 | 2022 | |
| Halozyme INC | $57.80 | 2023 | |
| Medicomp INC | $46.13 | 2025 | Telepatch Cardiac Monitor |
| Inspire Medical Systems, INC. | $33.10 | 2025 | Inspire |
| Kiniksa Pharmaceuticals, LTD. | $26.45 | 2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $26.04 | 2025 | |
| Janssen Pharmaceuticals, INC | $24.79 | 2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $23.67 | 2024 | Arcalyst |
| Azurity Pharmaceuticals, INC. | $19.97 | 2025 | Azmiro |
| Echosens North America, INC. | $16.07 | 2025 | Fibroscan |
| Currax Pharmaceuticals LLC | $15.83 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul O'Connell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.